GBT NASDAQ
Global Blood Therapeutics, Inc.
1W: +0.5%
1M: +1.0%
3M: +104.5%
1Y: +162.2%
3Y: +39.8%
5Y: +120.9%
$68.49
Last traded 2022-10-04 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$195M
+57.3% ▲
Gross Profit
$191M
+57.1% ▲
Operating Income
-$287M
-18.1% ▼
Net Income
-$303M
-22.4% ▼
EPS (Diluted)
$-4.82
-19.3% ▼
EBITDA
-$279M
-22.7% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $2M | $124M | $195M |
| YoY Growth | +0.0% | +0.0% | +0.0% | +5773.0% | +57.3% |
| Cost of Revenue | $0 | $0 | $48K | $2M | $3M |
| Gross Profit | $0 | $0 | $2M | $122M | $191M |
| Gross Margin | — | — | 97.7% | 98.4% | 98.3% |
| R&D Expenses | $88M | $131M | $175M | $155M | $212M |
| SG&A Expenses | $31M | $51M | $117M | $211M | $267M |
| Operating Expenses | $119M | $183M | $292M | $366M | $479M |
| Operating Income | -$119M | -$183M | -$281M | -$243M | -$287M |
| Operating Margin | — | — | -13343.6% | -196.4% | -147.4% |
| Interest Expense | $0 | $0 | $0 | $10M | $15M |
| Income Before Tax | -$117M | -$174M | -$267M | -$248M | -$303M |
| Tax Expense | $0 | $0 | $0 | $0 | $477K |
| Net Income | -$117M | -$174M | -$267M | -$248M | -$303M |
| Net Margin | — | — | -12654.9% | -200.0% | -155.6% |
| EPS (Diluted) | $-2.76 | $-3.41 | $-4.57 | $-4.04 | $-4.82 |
| EBITDA | -$115M | -$170M | -$257M | -$227M | -$279M |
| Shares Outstanding | 42M | 51M | 58M | 61M | 63M |